An indirect comparison of everolimus versus sorafenib in metastatic renal cell carcinoma – a flawed analysis and a problematic response

An indirect comparison of everolimus versus sorafenib in metastatic renal cell carcinoma – a flawed analysis?

(2012) David C Hoaglin et al.   EXPERT OPINION ON PHARMACOTHERAPY

Authors reply: an adjusted indirect comparison of everolimus and sorafenib therapy in sunitinib-refractory metastatic renal cell carcinoma patients using repeated matched samples

(2012) Giuseppe Di Lorenzo et al.   EXPERT OPINION ON PHARMACOTHERAPY

An adjusted indirect comparison of everolimus and sorafenib therapy in sunitinib-refractory metastatic renal cell carcinoma patients using repeated matched samples

(2011) Giuseppe Di Lorenzo et al.   EXPERT OPINION ON PHARMACOTHERAPY

Phase 3 trial of everolimus for metastatic renal cell carcinoma

(2010) Robert J. Motzer et al.   CANCER

Comparative Effectiveness Without Head-to-Head Trials

(2010) James E. Signorovitch et al.   PHARMACOECONOMICS

Direct versus indirect comparisons: A summary of the evidence

(2008) Gerald Gartlehner et al.   INTERNATIONAL JOURNAL OF TECHNOLOGY ASSESSMENT IN HEALTH CARE